Results 141 to 150 of about 636,170 (221)

Combination of FTO and BTK inhibitors synergistically suppresses the malignancy of breast cancer cells. [PDF]

Int J Biol Sci
Saad AAA, Ge L, Wang H, Xia Y, Li J, Qiao S, Yi C, Wang X, Wang Z, Zhou D, Wang H.   +10 more
europepmc   +1 more source

An Assessment of Kinase Selectivity, Enzyme Inhibition Kinetics and in Vitro Activity for Several Bruton Tyrosine Kinase (BTK) Inhibitors. [PDF]

ACS Pharmacol Transl Sci
Corrionero A, Zhang X, Alfonso P, Morris PJ, Klumpp-Thomas C, Melani C, McKnight C, Phelan JD, Holland D, Wilson K, Hoyt SB, Roschewski M, Tonge PJ, Wilson W, Ceribelli M, Staudt LM, Thomas CJ.   +16 more
europepmc   +1 more source

Real-world comparison of BTK inhibitors and lenalidomide as first-line maintenance in primary CNS lymphoma: a multi-center retrospective study. [PDF]

J Neurooncol
Chang X, He Z, Wang H, Zhu H, Guo Y, Zou D, Zhao Z, Song T, Hu R, Ni J, Zhao H, Hui W, Liu Z, Li Z, Zhang W, Zhou D, Zhang Y, Sun W.   +17 more
europepmc   +1 more source

Comparable outcomes of BTK inhibitors and fixed-duration venetoclax plus rituximab in second-line treatment of chronic lymphocytic leukaemia: a real-world analysis by the Czech CLL study group. [PDF]

Ann Hematol
Mihályová J, Panovská A, Šimkovič M, Smolej L, Špaček M, Shokralla T, Kubová Z, Zuchnická J, Arpáš T, Vodárek P, Turcsányi P, Polcerová L, Chrápavá M, Lysák D, Brejcha M, Móciková H, Doubek M.   +16 more
europepmc   +1 more source

Lights and shades of front-line treatment with covalent BTK inhibitors combined with venetoclax in patients with chronic lymphocytic leukemia. [PDF]

Oncol Rev
Visentin A, Mauro FR.
europepmc   +1 more source

Beyond relapses: How BTK inhibitors are shaping the future of progressive MS treatment. [PDF]

Neurotherapeutics
Naydovich LR, Orthmann-Murphy JL, Markowitz CE.   +2 more
europepmc   +1 more source

BTK Inhibitor M7583 [PDF]

, 2020
openaire   +1 more source

BTK inhibitors are a possible emerging therapeutic target for gastric cancer. [PDF]

Mol Ther Oncol
Portillo-Miño JD, Calderon JJ, Riquelme A.   +2 more
europepmc   +1 more source

Efficacy and Safety of Syk and BTK Inhibitors in Immune Thrombocytopenia: A Comprehensive Review of Emerging Evidence. [PDF]

Mediators Inflamm
Heidari A, Mazid AS, Behroozfar M, Ghotbi N, Fathabadi F, Eghbali S, Heidari N.   +6 more
europepmc   +1 more source